{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T06:09:50Z","timestamp":1785391790632,"version":"3.55.0"},"reference-count":50,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T00:00:00Z","timestamp":1666915200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"VISN-22 VA Center of Excellence for Stress and Mental Health"},{"name":"National Institute of Aging","award":["AG050595"],"award-info":[{"award-number":["AG050595"]}]},{"name":"National Institute of Aging","award":["VA MVP022"],"award-info":[{"award-number":["VA MVP022"]}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["#1F30CA247168"],"award-info":[{"award-number":["#1F30CA247168"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["#T32CA067754"],"award-info":[{"award-number":["#T32CA067754"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000070","name":"NIBIB","doi-asserted-by":"publisher","award":["#K08EB026503"],"award-info":[{"award-number":["#K08EB026503"]}],"id":[{"id":"10.13039\/100000070","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005595","name":"University of California","doi-asserted-by":"publisher","award":["#C21CR2060"],"award-info":[{"award-number":["#C21CR2060"]}],"id":[{"id":"10.13039\/100005595","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Genetic scores may provide an objective measure of prostate cancer risk and thus inform screening decisions. We evaluated whether a polygenic hazard score based on 290 genetic variants (PHS290) is associated with prostate cancer risk in a diverse population, including Black men, who have higher average risk of prostate cancer death but are often treated as a homogeneously high-risk group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This was a retrospective analysis of the Million Veteran Program, a national, population-based cohort study of US military veterans conducted 2011-2021. Cox proportional hazards analyses tested for association of genetic and other risk factors (including self-reported race and ethnicity and family history) with age at death from prostate cancer, age at diagnosis of metastatic (nodal or distant) prostate cancer, and age at diagnosis of any prostate cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 590\u200a750 male participants were included. Median age at last follow-up was 69 years. PHS290 was associated with fatal prostate cancer in the full cohort and for each racial and ethnic group (P\u2009&amp;lt;\u2009.001). Comparing men in the highest 20% of PHS290 with those in the lowest 20% (based on percentiles from an independent training cohort), the hazard ratio for fatal prostate cancer was 4.42 (95% confidence interval = 3.91 to 5.02). When accounting for guideline-recommended risk factors (family history, race, and ethnicity), PHS290 remained a strong independent predictor of any, metastatic, and fatal prostate cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>PHS290 stratified US veterans of diverse ancestry for lifetime risk of prostate cancer, including metastatic and fatal cancer. Predicting genetic risk of lethal prostate cancer with PHS290 might inform individualized decisions about prostate cancer screening.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jnci\/djac199","type":"journal-article","created":{"date-parts":[[2022,10,28]],"date-time":"2022-10-28T09:49:56Z","timestamp":1666950596000},"page":"190-199","source":"Crossref","is-referenced-by-count":36,"title":["Polygenic risk of any, metastatic, and fatal prostate cancer in the Million Veteran Program"],"prefix":"10.1093","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7591-6035","authenticated-orcid":false,"given":"Meghana S","family":"Pagadala","sequence":"first","affiliation":[{"name":"Research Service, VA San Diego Healthcare System , San Diego, CA, USA"},{"name":"Medical Scientist Training Program, University of California San Diego , La Jolla, CA, USA"},{"name":"Biomedical Science Program, University of California San Diego , La Jolla, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Lynch","sequence":"additional","affiliation":[{"name":"VA Informatics and Computing Infrastructure, VA Salt Lake City Healthcare System (VINCI) , Salt Lake City, UT, USA"},{"name":"Department of Internal Medicine, Division of Epidemiology, University of Utah School of Medicine , Salt Lake City, UT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roshan","family":"Karunamuni","sequence":"additional","affiliation":[{"name":"Department of Radiation Medicine and Applied Sciences, University of California San Diego , La Jolla, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick R","family":"Alba","sequence":"additional","affiliation":[{"name":"VA Informatics and Computing Infrastructure, VA Salt Lake City Healthcare System (VINCI) , Salt Lake City, UT, USA"},{"name":"Department of Internal Medicine, Division of Epidemiology, University of Utah School of Medicine , Salt Lake City, UT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung Min","family":"Lee","sequence":"additional","affiliation":[{"name":"VA Informatics and Computing Infrastructure, VA Salt Lake City Healthcare System (VINCI) , Salt Lake City, UT, USA"},{"name":"Department of Internal Medicine, Division of Epidemiology, University of Utah School of Medicine , Salt Lake City, UT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatai Y","family":"Agiri","sequence":"additional","affiliation":[{"name":"VA Informatics and Computing Infrastructure, VA Salt Lake City Healthcare System (VINCI) , Salt Lake City, UT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tori","family":"Anglin","sequence":"additional","affiliation":[{"name":"VA Informatics and Computing Infrastructure, VA Salt Lake City Healthcare System (VINCI) , Salt Lake City, UT, USA"},{"name":"Department of Internal Medicine, Division of Epidemiology, University of Utah School of Medicine , Salt Lake City, UT, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Carter","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California San Diego , La Jolla, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J Michael","family":"Gaziano","sequence":"additional","affiliation":[{"name":"Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare System , Boston, MA, USA"},{"name":"Department of Medicine, Brigham and Women\u2019s Hospital , Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guneet Kaur","family":"Jasuja","sequence":"additional","affiliation":[{"name":"Center for Healthcare Organization and Implementation Research (CHOIR), VA Bedford Healthcare System , Bedford, MA, USA"},{"name":"Section of General Internal Medicine, Boston University School of Medicine , Boston, MA, USA ; , La Jolla, CA, USA"},{"name":"Department of Urology, University of California San Diego , Boston, MA, USA ; , La Jolla, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishi","family":"Deka","sequence":"additional","affiliation":[{"name":"Research Service, VA San Diego Healthcare System , San Diego, CA, USA"},{"name":"Department of Radiation Medicine and Applied Sciences, University of California San Diego , La Jolla, CA, USA"},{"name":"Department of Psychiatry, University of California San Diego , La Jolla, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brent S","family":"Rose","sequence":"additional","affiliation":[{"name":"Research Service, VA San Diego Healthcare System , San Diego, CA, USA"},{"name":"Department of Radiation Medicine and Applied Sciences, University of California San Diego , La Jolla, CA, USA"},{"name":"Section of General Internal Medicine, Boston University School of Medicine , Boston, MA, USA ; , La Jolla, CA, USA"},{"name":"Department of Urology, University of California San Diego , Boston, MA, USA ; , La Jolla, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S","family":"Panizzon","sequence":"additional","affiliation":[{"name":"Research Service, VA San Diego Healthcare System , San Diego, CA, USA"},{"name":"Center for Behavioral Genetics of Aging, University of California San Diego , La Jolla, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1509-1868","authenticated-orcid":false,"given":"Richard L","family":"Hauger","sequence":"additional","affiliation":[{"name":"Research Service, VA San Diego Healthcare System , San Diego, CA, USA"},{"name":"Center for Behavioral Genetics of Aging, University of California San Diego , La Jolla, CA, USA"},{"name":"Center of Excellence for Stress and Mental Health (CESAMH), VA San Diego Healthcare System , San Diego, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4089-7399","authenticated-orcid":false,"given":"Tyler M","family":"Seibert","sequence":"additional","affiliation":[{"name":"Research Service, VA San Diego Healthcare System , San Diego, CA, USA"},{"name":"Department of Radiation Medicine and Applied Sciences, University of California San Diego , La Jolla, CA, USA"},{"name":"Department of Radiology, University of California San Diego , La Jolla, CA, USA"},{"name":"Department of Bioengineering, University of California San Diego , La Jolla, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,10,28]]},"reference":[{"issue":"9959","key":"2023020808064710000_djac199-B1","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1016\/S0140-6736(14)60525-0","volume":"384","author":"Schr\u00f6der"},{"issue":"12","key":"2023020808064710000_djac199-B2","doi-asserted-by":"publisher","first-page":"e1002998","DOI":"10.1371\/journal.pmed.1002998","article-title":"Polygenic risk-tailored screening for prostate cancer: a benefit-harm and cost-effectiveness modelling study","volume":"16","author":"Callender","year":"2019","journal-title":"PLoS Med"},{"issue":"6","key":"2023020808064710000_djac199-B3","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.eururo.2013.12.062","article-title":"Overdiagnosis and overtreatment of prostate cancer","volume":"65","author":"Loeb","year":"2014","journal-title":"Eur Urol"},{"issue":"1","key":"2023020808064710000_djac199-B4","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1001\/jama.2015.17703","article-title":"Familial risk and heritability of cancer among twins in Nordic countries","volume":"315","author":"Mucci","year":"2016","journal-title":"JAMA"},{"issue":"9","key":"2023020808064710000_djac199-B5","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/s41576-018-0018-x","article-title":"The personal and clinical utility of polygenic risk scores","volume":"19","author":"Torkamani","year":"2018","journal-title":"Nat Rev Genet"},{"issue":"3","key":"2023020808064710000_djac199-B6","doi-asserted-by":"publisher","first-page":"e2037657","DOI":"10.1001\/jamanetworkopen.2020.37657","article-title":"Benefit, harm, and cost-effectiveness associated with magnetic resonance imaging before biopsy in age-based and risk-stratified screening for prostate cancer","volume":"4","author":"Callender","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2023020808064710000_djac199-B7","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j5757","article-title":"Polygenic hazard score to guide screening for aggressive prostate cancer: development and validation in large scale cohorts","author":"Seibert","journal-title":"BMJ"},{"issue":"2","key":"2023020808064710000_djac199-B8","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/s41588-018-0330-6","article-title":"Author correction: Association analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci","volume":"51","author":"Schumacher","year":"2019","journal-title":"Nat Genet"},{"issue":"3)","key":"2023020808064710000_djac199-B9","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1038\/s41391-021-00341-4","article-title":"Common genetic and clinical risk factors: association with fatal prostate cancer in the Cohort of Swedish Men","volume":"24","author":"Huynh-Le","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"2","key":"2023020808064710000_djac199-B10","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/s41391-020-00311-2","article-title":"Additional SNPs improve risk stratification of a polygenic hazard score for prostate cancer","volume":"24","author":"Karunamuni","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"8","key":"2023020808064710000_djac199-B11","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1002\/cncr.32702","article-title":"Age dependence of modern clinical risk groups for localized prostate cancer-a population-based study","volume":"126","author":"Huynh-Le","year":"2020","journal-title":"Cancer"},{"issue":"9","key":"2023020808064710000_djac199-B12","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1158\/1055-9965.EPI-19-1527","article-title":"A genetic risk score to personalize prostate cancer screening, applied to population data","volume":"29","author":"Huynh-Le","year":"2020","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"2023020808064710000_djac199-B13","doi-asserted-by":"publisher","first-page":"3328","DOI":"10.1038\/s41467-019-11112-0","article-title":"Analysis of polygenic risk score usage and performance in diverse human populations","volume":"10","author":"Duncan","year":"2019","journal-title":"Nat Commun"},{"issue":"1","key":"2023020808064710000_djac199-B14","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s13059-016-1016-y","article-title":"Unequal representation of genetic variation across ancestry groups creates healthcare inequality in the application of precision medicine","volume":"17","author":"Petrovski","year":"2016","journal-title":"Genome Biol"},{"issue":"4","key":"2023020808064710000_djac199-B15","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/s41588-019-0379-x","article-title":"Clinical use of current polygenic risk scores may exacerbate health disparities","volume":"51","author":"Martin","year":"2019","journal-title":"Nat Genet"},{"issue":"7624","key":"2023020808064710000_djac199-B16","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/538161a","article-title":"Genomics is failing on diversity","volume":"538","author":"Popejoy","year":"2016","journal-title":"Nature"},{"issue":"3","key":"2023020808064710000_djac199-B17","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3322\/caac.21555","article-title":"Cancer statistics for African Americans, 2019","volume":"69","author":"DeSantis","year":"2019","journal-title":"CA Cancer J Clin."},{"issue":"12","key":"2023020808064710000_djac199-B18","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1002\/cncr.30687","article-title":"Is prostate cancer different in Black men? Answers from 3 natural history models","volume":"123","author":"Tsodikov","year":"2017","journal-title":"Cancer"},{"issue":"1","key":"2023020808064710000_djac199-B19","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1002\/ijc.33282","article-title":"African-specific improvement of a polygenic hazard score for age at diagnosis of prostate cancer","volume":"148","author":"Karunamuni","year":"2021","journal-title":"Int J Cancer"},{"issue":"2","key":"2023020808064710000_djac199-B20","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/s41391-021-00403-7","article-title":"Performance of African-ancestry-specific polygenic hazard score varies according to local ancestry in 8q24","volume":"25","author":"Karunamuni","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"1","key":"2023020808064710000_djac199-B21","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41588-020-00748-0","article-title":"Trans-ancestry genome-wide association meta-analysis of prostate cancer identifies new susceptibility loci and informs genetic risk prediction","volume":"53","author":"Conti","year":"2021","journal-title":"Nat Genet"},{"issue":"1","key":"2023020808064710000_djac199-B22","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1038\/s41467-021-21287-0","article-title":"Polygenic hazard score is associated with prostate cancer in multi-ethnic populations","volume":"12","author":"Huynh-Le","year":"2021","journal-title":"Nat Commun"},{"key":"2023020808064710000_djac199-B23","doi-asserted-by":"publisher","DOI":"10.1038\/s41391-022-00497-7","article-title":"Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score","author":"Huynh-Le","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2023020808064710000_djac199-B24","doi-asserted-by":"publisher","DOI":"10.1101\/2021.08.14.21261931","article-title":"Prostate cancer risk stratification improved across multiple ancestries with new polygenic hazard score","author":"Huynh-Le","year":"2021","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"2023020808064710000_djac199-B25","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.jclinepi.2015.09.016","article-title":"Million Veteran Program: a mega-biobank to study genetic influences on health and disease","volume":"70","author":"Gaziano","year":"2016","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"2023020808064710000_djac199-B26","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.ajhg.2020.03.004","article-title":"Genotyping array design and data quality control in the Million Veteran Program","volume":"106","author":"Hunter-Zinck","year":"2020","journal-title":"Am J Hum Genet"},{"issue":"10","key":"2023020808064710000_djac199-B27","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/s41431-020-0664-2","article-title":"The effect of sample size on polygenic hazard models for prostate cancer","volume":"28","author":"Karunamuni","year":"2020","journal-title":"Eur J Hum Genet"},{"issue":"18","key":"2023020808064710000_djac199-B28","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1001\/jama.1982.03320430047030","article-title":"Evaluating the yield of medical tests","volume":"247","author":"Harrell","year":"1982","journal-title":"JAMA"},{"issue":"7","key":"2023020808064710000_djac199-B29","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1056\/NEJMra1701695","article-title":"Metastatic prostate cancer","volume":"378","author":"Sartor","year":"2018","journal-title":"N Engl J Med"},{"key":"2023020808064710000_djac199-B30","author":"Moses","year":"2021"},{"issue":"2","key":"2023020808064710000_djac199-B31","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3322\/caac.20066","article-title":"American Cancer Society guideline for the early detection of prostate cancer: update 2010","volume":"60","author":"Wolf","year":"2010","journal-title":"CA Cancer J Clin."},{"issue":"5","key":"2023020808064710000_djac199-B32","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1093\/annonc\/mds624","article-title":"Prostate cancer: ESMO Consensus Conference Guidelines 2012","volume":"24","author":"Horwich","year":"2013","journal-title":"Ann Oncol"},{"issue":"10","key":"2023020808064710000_djac199-B33","doi-asserted-by":"publisher","first-page":"761","DOI":"10.7326\/0003-4819-158-10-201305210-00633","article-title":"Screening for prostate cancer: a guidance statement from the Clinical Guidelines Committee of the American College of Physicians","volume":"158","author":"Qaseem","year":"2013","journal-title":"Ann Intern Med"},{"issue":"12","key":"2023020808064710000_djac199-B34","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1002\/cncr.28042","article-title":"Association between race and follow-up diagnostic care after a positive prostate cancer screening test in the prostate, lung, colorectal, and ovarian cancer screening trial","volume":"119","author":"Barocas","year":"2013","journal-title":"Cancer"},{"issue":"7","key":"2023020808064710000_djac199-B35","doi-asserted-by":"publisher","first-page":"djv431","DOI":"10.1093\/jnci\/djv431","article-title":"Prostate cancer susceptibility in men of African ancestry at 8q24","volume":"108","author":"Han","year":"2016","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"2023020808064710000_djac199-B36","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/j.urology.2014.05.009","article-title":"Trends in disparate treatment of African American men with localized prostate cancer across National Comprehensive Cancer Network risk groups","volume":"84","author":"Mahal","year":"2014","journal-title":"Urology"},{"issue":"25","key":"2023020808064710000_djac199-B37","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1200\/JCO.2014.59.8912","article-title":"Novel biomarker signature that may predict aggressive disease in African American men with prostate cancer","volume":"33","author":"Yamoah","year":"2015","journal-title":"J Clin Oncol"},{"key":"2023020808064710000_djac199-B38","doi-asserted-by":"publisher","first-page":"312","DOI":"10.3389\/fonc.2013.00312","article-title":"Age and racial differences among PSA-detected (AJCC stage T1cN0M0) prostate cancer in the U.S.: a population-based study of 70,345 men","volume":"3","author":"Zhang","year":"2013","journal-title":"Front Oncol"},{"issue":"3","key":"2023020808064710000_djac199-B39","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.eururo.2020.11.014","article-title":"Performance of three inherited risk measures for predicting prostate cancer incidence and mortality: a population-based prospective analysis","volume":"79","author":"Shi","year":"2021","journal-title":"Eur Urol"},{"issue":"1","key":"2023020808064710000_djac199-B40","doi-asserted-by":"publisher","first-page":"6084","DOI":"10.1038\/s41467-020-19600-4","article-title":"Pan-cancer analysis demonstrates that integrating polygenic risk scores with modifiable risk factors improves risk prediction","volume":"11","author":"Kachuri","year":"2020","journal-title":"Nat Commun"},{"issue":"14","key":"2023020808064710000_djac199-B41","doi-asserted-by":"publisher","first-page":"3369","DOI":"10.1002\/cncr.24365","article-title":"Agent Orange exposure, Vietnam war veterans, and the risk of prostate cancer","volume":"115","author":"Schecter","year":"2009","journal-title":"Cancer"},{"key":"2023020808064710000_djac199-B42","doi-asserted-by":"publisher","first-page":"f2023","DOI":"10.1136\/bmj.f2023","article-title":"Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study","volume":"346","author":"Vickers","year":"2013","journal-title":"BMJ"},{"issue":"4","key":"2023020808064710000_djac199-B43","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1200\/JCO.2006.06.9351","article-title":"Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate Kallikreins measured at age 44 to 50 years","volume":"25","author":"Lilja","year":"2007","journal-title":"J Clin Oncol"},{"issue":"3","key":"2023020808064710000_djac199-B44","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.eururo.2018.08.032","article-title":"Baseline prostate-specific antigen level in midlife and aggressive prostate cancer in black men","volume":"75","author":"Preston","year":"2019","journal-title":"Eur Urol"},{"issue":"18","key":"2023020808064710000_djac199-B45","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1001\/jama.2018.3710","article-title":"Screening for prostate cancer","volume":"319","author":"Grossman","year":"2018","journal-title":"JAMA"},{"issue":"1","key":"2023020808064710000_djac199-B46","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/s41698-022-00266-8","article-title":"Prostate cancer polygenic risk score and prediction of lethal prostate cancer","volume":"6","author":"Klein","year":"2022","journal-title":"NPJ Precis Oncol"},{"issue":"10","key":"2023020808064710000_djac199-B47","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1056\/NEJMoa2100852","article-title":"MRI-targeted or standard biopsy in prostate cancer screening","volume":"385","author":"Eklund","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"2023020808064710000_djac199-B48","doi-asserted-by":"publisher","first-page":"100070","DOI":"10.1016\/j.xhgg.2021.100070","article-title":"Genetic factors associated with prostate cancer conversion from active surveillance to treatment","volume":"3","author":"Jiang","year":"2022","journal-title":"HGG Adv"},{"issue":"2","key":"2023020808064710000_djac199-B49","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41391-019-0181-y","article-title":"Germline genetic variation in prostate susceptibility does not predict outcomes in the chemoprevention trials PCPT and SELECT","volume":"23","author":"Ahmed","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"2023020808064710000_djac199-B50","doi-asserted-by":"crossref","DOI":"10.1016\/j.eururo.2022.05.008","article-title":"A healthy lifestyle in men at increased genetic risk for prostate cancer","author":"Plym","year":"2022","journal-title":"Eur Urol."}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jnci\/advance-article-pdf\/doi\/10.1093\/jnci\/djac199\/48001162\/djac199.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/115\/2\/190\/49113334\/djac199.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jnci\/article-pdf\/115\/2\/190\/49113334\/djac199.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T03:21:54Z","timestamp":1675826514000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article\/115\/2\/190\/6777270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,28]]},"references-count":50,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,10,28]]},"published-print":{"date-parts":[[2023,2,8]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djac199","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2021.09.24.21264093","asserted-by":"object"}]},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,2,1]]},"published":{"date-parts":[[2022,10,28]]}}}